| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.41▲ | 1.41▲ | 1.41▲ | 1.44▼ | 1.43▼ |
| MA10 | 1.41▲ | 1.41▼ | 1.43▼ | 1.44▼ | 1.46▼ |
| MA20 | 1.43▼ | 1.43▼ | 1.43▼ | 1.44▼ | 1.61▼ |
| MA50 | 1.43▼ | 1.42▼ | 1.45▼ | 1.47▼ | 1.93▼ |
| MA100 | 1.45▼ | 1.45▼ | 1.45▼ | 1.65▼ | 2.10▼ |
| MA200 | 1.46▼ | 1.49▼ | 1.55▼ | 1.96▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.003▼ | -0.003▼ | 0.000▼ | -0.001▼ |
| RSI | 45.679▼ | 44.935▼ | 44.280▼ | 44.033▼ | 40.937▼ |
| STOCH | 23.810 | 17.857▼ | 9.524▼ | 33.518 | 27.555 |
| WILL %R | -85.714▼ | -85.714▼ | -85.714▼ | -65.385 | -71.459 |
| CCI | -46.667 | -50.256 | -73.810 | -70.604 | -100.134▼ |
|
Wednesday, August 26, 2026 03:49 PM
IBRX's aggressive R&D spend, weak financials, and emerging competition from TAR-200 and cretostimogene pose risks to future value realization. Click to read.
|
|
Thursday, August 13, 2026 07:57 PM
CG Oncology (CGON) advances cret for NMIBC with strong CR rates and best-in-class safety; see trial results and 2026–2027 catalysts. See more here.
|
|
Thursday, August 13, 2026 07:47 AM
BCG Leader Daniel Friedman joins Kristen Scholer on NYSE Live to discuss the M&A market after gains ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/08/26 | 1.41 | 1.42 | 1.38 | 1.395 | 16,555 |
| 27/08/26 | 1.45 | 1.46 | 1.4101 | 1.45 | 19,513 |
| 26/08/26 | 1.42 | 1.46 | 1.39 | 1.45 | 22,413 |
| 25/08/26 | 1.47 | 1.4799 | 1.41 | 1.445 | 17,453 |
| 24/08/26 | 1.45 | 1.46 | 1.435 | 1.45 | 24,991 |
| 21/08/26 | 1.38 | 1.4263 | 1.38 | 1.40 | 18,242 |
| 20/08/26 | 1.39 | 1.49 | 1.37 | 1.40 | 38,125 |
| 19/08/26 | 1.50 | 1.5099 | 1.375 | 1.39 | 84,603 |
| 18/08/26 | 1.53 | 1.555 | 1.49 | 1.50 | 30,205 |
| 17/08/26 | 1.58 | 1.58 | 1.525 | 1.56 | 47,195 |
|
|
||||
|
|
||||
|
|